Brillancesp. z o.o.

Other research and experimental development on natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2004-02-12
Share capital
50 000,00 PLN
Activity description

Brillance is an independent CRO supporting biotech companies and CRO partners with clinical trials in Poland, the Czech Republic and Slovakia, from feasibility and start-up to study close-out, including clinical operations, regulatory support and project management. It conducts Phase I–IV medicinal product studies and medical device clinical investigations, including work in neurology, psychiatry, oncology and hemato-oncology. Founded in 2004 and headquartered in Krakow, the company has completed more than 268 clinical projects with a team of around 50 specialists.

Registered address
ul. Zarzecze 136 A, 30-134 Kraków, Poland
Phone
Social media
Electronic delivery address
AE:PL-75276-38169-IIHEF-21

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 97 days early.

  • 202526/03/2026
  • 202427/03/2025
  • 202325/03/2024
  • 202231/03/2023
  • 202115/06/2022
  • 202024/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 3.33mMedianUSD 73.59kAverageUSD 3.23m
Net profit
This companyUSD 598.39kMedianUSD 68.18AverageUSD 82.15k
Operating costs
This companyUSD 2.51mMedianUSD 76.09kAverageUSD 3.04m
Assets
This companyUSD 1.19mMedianUSD 120.07kAverageUSD 3.90m

Offer

  • Clinical trial coordination
  • Clinical trial monitoring
  • Clinical site selection
  • Clinical project management
  • Medical device clinical trials
  • Clinical trial participant recruitment
  • Clinical research training

Public procurement

Brillance is the contractor in one public sector contract, worth USD 378.17.

SubjectAmount
Training: “Set-up Badania Klinicznego dla Monitorów, Koordynatorów i Administratorów”
$378.17

Authorized Representatives

Paweł Dyras – President of the Management Board

Manner of representation

The President and the Vice-President of the Management Board are each authorized to represent the company externally independently; in all other cases, action by two members of the management board or by a member of the management board jointly with a commercial proxy is required.

Supervisory board

Bożena Wodka Micał – Supervisory Board Member
Zygmunt Dyras – Supervisory Board Member
Małgorzata Liber – Supervisory Board Member

Ownership

OwnerSharesShare valueStake
Paweł Dyrasage 63
1,000$13,506.21100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2004-07-06.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

4 public aid cases recorded, with a total value of $60,281.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$3,722
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$17,630
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$19,608

Change history

DateEvent
2026-07-07Address change
2017-08-31PKD change
2011-02-04Address change
2010-10-22PKD change
2005-02-24Address change

FAQ

Last updated: 2026-10-07